Curesponse’s 3D drug sensitivity assay presents an enormous opportunity for pharma companies working on drug development and clinical trials. Instead of evaluating drug efficacy on cell lines and PDX models which poorly reflect the cancer’s activity in vivo and are very costly, companies can now use EVOC for development, quickly evaluating the potential and activity of their candidates on active human tissue. Furthermore, EVOC can function as a companion assay for drugs in clinical trials to predict whether the patient will respond to therapy, allowing investigators to target the population most sensitive to the drug and increase their trials success rates.
Curesponse provides a personalized cancer treatment regimen by analyzing the patient’s cancer drug response. Instead of guess work and conjectures, our platform shows a functionally accurate answer for patient therapy. Patients can send a sample of their cancer to the Curesponse lab and within 2 weeks receive a report describing treatment prioritization. Currently the technology is in clinical trials at numerous leading medical centers involved in cutting edge cancer treatment.